Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City

Christine Tagliaferri Rael; Michelle Martinez; Rebecca Giguere; Walter Bockting; Caitlin MacCrate; Will Mellman; Pablo Valente; George J. Greene; Susan Sherman; Katherine H.A. Footer; Richard T. D’Aquila; Alex Carballo-Diéguez

doi:10.1007/s10461-018-2102-9

Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City

Christine Tagliaferri Rael, Michelle Martinez, Rebecca Giguere, Walter Bockting, Caitlin MacCrate, Will Mellman, Pablo Valente, George J. Greene, Susan Sherman, Katherine H.A. Footer, Richard T. D’Aquila, Alex Carballo-Diéguez

Bloomberg School of Public Health

Research output: Contribution to journal › Article › peer-review

Abstract

Transgender women may face a disparate risk for HIV/AIDS compared to other groups. In 2012, Truvada was approved for daily use as HIV pre-exposure prophylaxis (PrEP). However, there is a dearth of research about barriers and facilitators to PrEP in transgender women. This paper will shed light on transgender women living in New York City’s perceived and actual challenges to using PrEP and potential strategies to overcome them. After completing an initial screening process, four 90-min focus groups were completed with n = 18 transgender women. Participants were asked what they like and dislike about PrEP. Participants identified the following barriers: uncomfortable side effects, difficulty taking pills, stigma, exclusion of transgender women in advertising, and lack of research on transgender women and PrEP. Facilitators included: reducing pill size, increasing the types of available HIV prevention products, and conducting scientific studies to evaluate PrEP in transgender women.

Original language	English (US)
Pages (from-to)	3627-3636
Number of pages	10
Journal	AIDS and behavior
Volume	22
Issue number	11
DOIs	https://doi.org/10.1007/s10461-018-2102-9
State	Published - Nov 1 2018

Keywords

Barriers
Facilitators
HIV prevention
PrEP
Transgender women
Transwomen

ASJC Scopus subject areas

Social Psychology
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1007/s10461-018-2102-9

Cite this

Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City. / Rael, Christine Tagliaferri; Martinez, Michelle; Giguere, Rebecca; Bockting, Walter; MacCrate, Caitlin; Mellman, Will; Valente, Pablo; Greene, George J.; Sherman, Susan; Footer, Katherine H.A.; D’Aquila, Richard T.; Carballo-Diéguez, Alex.

In: AIDS and behavior, Vol. 22, No. 11, 01.11.2018, p. 3627-3636.

Research output: Contribution to journal › Article › peer-review

Rael, Christine Tagliaferri ; Martinez, Michelle ; Giguere, Rebecca ; Bockting, Walter ; MacCrate, Caitlin ; Mellman, Will ; Valente, Pablo ; Greene, George J. ; Sherman, Susan ; Footer, Katherine H.A. ; D’Aquila, Richard T. ; Carballo-Diéguez, Alex. / Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City. In: AIDS and behavior. 2018 ; Vol. 22, No. 11. pp. 3627-3636.

@article{47ab51c18f4c440580c5f8960f714141,

title = "Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City",

abstract = "Transgender women may face a disparate risk for HIV/AIDS compared to other groups. In 2012, Truvada was approved for daily use as HIV pre-exposure prophylaxis (PrEP). However, there is a dearth of research about barriers and facilitators to PrEP in transgender women. This paper will shed light on transgender women living in New York City{\textquoteright}s perceived and actual challenges to using PrEP and potential strategies to overcome them. After completing an initial screening process, four 90-min focus groups were completed with n = 18 transgender women. Participants were asked what they like and dislike about PrEP. Participants identified the following barriers: uncomfortable side effects, difficulty taking pills, stigma, exclusion of transgender women in advertising, and lack of research on transgender women and PrEP. Facilitators included: reducing pill size, increasing the types of available HIV prevention products, and conducting scientific studies to evaluate PrEP in transgender women.",

keywords = "Barriers, Facilitators, HIV prevention, PrEP, Transgender women, Transwomen",

author = "Rael, {Christine Tagliaferri} and Michelle Martinez and Rebecca Giguere and Walter Bockting and Caitlin MacCrate and Will Mellman and Pablo Valente and Greene, {George J.} and Susan Sherman and Footer, {Katherine H.A.} and D{\textquoteright}Aquila, {Richard T.} and Alex Carballo-Di{\'e}guez",

note = "Funding Information: Funding Data collection support was provided by Project AFFIRM (R01 HD079603; Principle Investigator, Walter Bockting, Ph.D.) and a generous grant from the Mac AIDS Fund (MAF CU13-3233). The first author is supported by a training grant (T32 MH019139; Principle Investigator, Theodorus Sandfort, Ph.D.) from the National Institute of Mental Health at the HIV Center for Clinical and Behavioral Studies at the NY State Psychiatric Institute and Columbia University (P30 MH43520; Center Principle Investigator: Robert Remien, Ph.D.). Additionally, research was supported by SLAP-HIV (UM1 AI120184; Principle Investigator, Tomas Hope, Ph.D.) and the Third Coast Center for AIDS Research (P30 AI117943; Principle Investigator, Richard D{\textquoteright}Aquila, M.D.). Publisher Copyright: {\textcopyright} 2018, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2018",

month = nov,

day = "1",

doi = "10.1007/s10461-018-2102-9",

language = "English (US)",

volume = "22",

pages = "3627--3636",

journal = "AIDS and Behavior",

issn = "1090-7165",

publisher = "Springer New York",

number = "11",

}

TY - JOUR

T1 - Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City

AU - Rael, Christine Tagliaferri

AU - Martinez, Michelle

AU - Giguere, Rebecca

AU - Bockting, Walter

AU - MacCrate, Caitlin

AU - Mellman, Will

AU - Valente, Pablo

AU - Greene, George J.

AU - Sherman, Susan

AU - Footer, Katherine H.A.

AU - D’Aquila, Richard T.

AU - Carballo-Diéguez, Alex

N1 - Funding Information: Funding Data collection support was provided by Project AFFIRM (R01 HD079603; Principle Investigator, Walter Bockting, Ph.D.) and a generous grant from the Mac AIDS Fund (MAF CU13-3233). The first author is supported by a training grant (T32 MH019139; Principle Investigator, Theodorus Sandfort, Ph.D.) from the National Institute of Mental Health at the HIV Center for Clinical and Behavioral Studies at the NY State Psychiatric Institute and Columbia University (P30 MH43520; Center Principle Investigator: Robert Remien, Ph.D.). Additionally, research was supported by SLAP-HIV (UM1 AI120184; Principle Investigator, Tomas Hope, Ph.D.) and the Third Coast Center for AIDS Research (P30 AI117943; Principle Investigator, Richard D’Aquila, M.D.). Publisher Copyright: © 2018, Springer Science+Business Media, LLC, part of Springer Nature.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Transgender women may face a disparate risk for HIV/AIDS compared to other groups. In 2012, Truvada was approved for daily use as HIV pre-exposure prophylaxis (PrEP). However, there is a dearth of research about barriers and facilitators to PrEP in transgender women. This paper will shed light on transgender women living in New York City’s perceived and actual challenges to using PrEP and potential strategies to overcome them. After completing an initial screening process, four 90-min focus groups were completed with n = 18 transgender women. Participants were asked what they like and dislike about PrEP. Participants identified the following barriers: uncomfortable side effects, difficulty taking pills, stigma, exclusion of transgender women in advertising, and lack of research on transgender women and PrEP. Facilitators included: reducing pill size, increasing the types of available HIV prevention products, and conducting scientific studies to evaluate PrEP in transgender women.

AB - Transgender women may face a disparate risk for HIV/AIDS compared to other groups. In 2012, Truvada was approved for daily use as HIV pre-exposure prophylaxis (PrEP). However, there is a dearth of research about barriers and facilitators to PrEP in transgender women. This paper will shed light on transgender women living in New York City’s perceived and actual challenges to using PrEP and potential strategies to overcome them. After completing an initial screening process, four 90-min focus groups were completed with n = 18 transgender women. Participants were asked what they like and dislike about PrEP. Participants identified the following barriers: uncomfortable side effects, difficulty taking pills, stigma, exclusion of transgender women in advertising, and lack of research on transgender women and PrEP. Facilitators included: reducing pill size, increasing the types of available HIV prevention products, and conducting scientific studies to evaluate PrEP in transgender women.

KW - Barriers

KW - Facilitators

KW - HIV prevention

KW - PrEP

KW - Transgender women

KW - Transwomen

UR - http://www.scopus.com/inward/record.url?scp=85044479485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044479485&partnerID=8YFLogxK

U2 - 10.1007/s10461-018-2102-9

DO - 10.1007/s10461-018-2102-9

M3 - Article

C2 - 29589137

AN - SCOPUS:85044479485

VL - 22

SP - 3627

EP - 3636

JO - AIDS and Behavior

JF - AIDS and Behavior

SN - 1090-7165

IS - 11

ER -

Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this